Background: Pleural infection is a common complication of pneumonia associated with high mortality and poor clinical outcome. Treatment of pleural infection relies on the use of broad-spectrum antibiotics, since reliable pathogen identification occurs infrequently. We performed a feasibility interventional clinical trial assessing the safety and significance of ultrasound (US)-guided pleural biopsy culture to increase the microbiological yield.

Methods: 20 patients with clinically established pleural infection were recruited. Participants underwent a detailed US scan and US-guided pleural biopsies before chest drain insertion, alongside standard clinical management. Pleural biopsies and routine clinical samples (pleural fluid and blood) were submitted for microbiological analysis. In an exploratory sub-study, the 16S rRNA technique was applied on pleural biopsy samples, to investigate its utility on increasing speed and accuracy versus standard microbiological diagnosis. This trial is registered with ClinicalTrials.gov, number NCT02608814.

Findings: US-guided biopsies were safe with no adverse events observed in this study. Pleural biopsies increased microbiological yield by 30% in addition to pleural fluid and blood samples (combined diagnostic sensitivity 55%). US characteristics at baseline were not statistically associated with survival, fluid volume drainage, radiological improvement or need for surgery. The 16S rRNA technique was successfully applied to pleural biopsy samples, demonstrating high sensitivity (93%) and specificity (89.5%).

Conclusion: Our findings demonstrate safety of conducting US-guided biopsies in patients with pleural infection and a substantial increase in microbiological diagnosis. qPCR primer assessment of pleural fluid and biopsy appears to have excellent sensitivity and specificity.

Funding: Oxfordshire Health Services Research Committee.

Abstract S25 Figure 1  Kaplan-meier survival curves for Eosinophilic vs Non-Eosinophilic effusions.
marker of benign disease, however, subsequent studies found malignancy to be the commonest aetiology,\(^1\) with other causes, including infection, blood/air and drug reactions less frequent. Our aim is to use prospective data to examine the relative incidence and aetiology of EPE, and its prognostic significance. 

**Methods** We recruited 803 consecutive patients presenting to a pleural service, between 03/2008 and 03/2015, with undiagnosed pleural effusions. Pleural biochemistry, cytology, thoracic USS, chest radiograph and CT scans were performed. Biopsies and thoracoscopy were performed as clinically indicated. Patients were followed-up for minimum duration of 12 months with final diagnosis decided by independent review by 2 respiratory consultants. Survival data was calculated from study entry to death and censored on 07/2017. 

**Results** Of the 803 patients, 398/803 (49.6\%) had a malignant pleural effusion (MPE). 57 (7.1\%) had eosinophil count (EC) \(\geq 10\%\). With this threshold, MPE was the commonest cause, at 24/57 (42\%), followed by infection 9 (16\%) and inflammatory pleuritis (IP) 5 (9\%). With higher thresholds of EC, the relative frequency of malignancy decreased. At \(\geq 30\%\) EC, malignancy accounted for 4/20 cases, infection 4/20, drug/toxin 3/20, unknown 3/20, benign asbestos pleural effusion 2/20, pulmonary embolism 2/20, IP 1/20 and heart failure 1/20. Mortality rates were lower in EPE relative to non-EPE, with 6 months and 1 year mortality rates for EPE 19\%–33\% respectively, with non-EPE 36\%–50\%. The higher the EC, the lower mortality, with hazard ratios compared to non-EPE at 0.6, 0.5, 0.3, 0.2, 0.2 for \(\geq 10\%, \geq 20\%, \geq 30\%, \geq 40\%\) and \(\geq 50\%\) EC respectively (\(p<0.01\)).

**Conclusion** Higher eosinophil counts are associated with decreased mortality and lower rates of malignant vs benign effusions. The threshold \(\geq 10\%\) is not helpful in differentiating MPE from benign disease. We suggest a higher threshold of \(\geq 30\%\) would hold greater clinical significance and therefore be a more useful definition for clinicians.

**REFERENCE**

---

**Abstract S26**

**Identification and Prognostic Importance of Non-Expansile Lung Following Drainage of Suspected Malignant Pleural Effusion**

GA Martin, AC Kidd, S Tsim, KG Blyth. Queen Elizabeth University Hospital, Glasgow, UK

**Introduction** Malignant Pleural Effusion (MPE) is common and often Results in disabling breathlessness. Non-expansile lung (NEL) frequently complicates pleural drainage, resulting in talc pleurodesis failure. Reliable detection of NEL would allow better clinical decision-making and more rational design of

---

**Abstract S26 Figure 1** Semi-objective definitions of non-expansile lung (NEL) including worked examples and screenshots from Vue PACS v13 (Carestream Health Inc., Rochester, NY).